HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...

Although advanced urothelial carcinoma is a common and relatively chemosensitive neoplasm, it still remains a fatal disease. Over the last 10 years or so chemotherapy of advanced urothelial tumours ...

BeOne Medicines, a global oncology company, today announced that Health Canada has granted a Notice of Compliance (NOC), approving TEVIMBRA® (tislelizumab for injection) in combination with ...

Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use ...

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma Eligible patients were randomly assigned to receive nimotuzumab (400 mg ...

Impact of Cancer Awareness Drive on Generating Awareness of and Improving Screening for Cervical Cancer: A Study Among Schoolteachers in India Of 70 participants enrolled, 36 received gemcitabine and ...

Please provide your email address to receive an email when new articles are posted on . Antibiotic receipt in the month before or after gemcitabine treatment improved survival in metastatic pancreatic ...

U.S. Food and Drug Administration Approves ABRAXANE® in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer -Approval Based on MPACT Study of ABRAXANE in ...

Median Survival of 12.2 Months 50 Percent Response Rate 68 Percent Disease Control Decrease in CA19-9 Tumor Biomarker Levels in 100 Percent of Patients Treated The biomarker CA19-9 is a ...